� Interlace Medical br (interlaced), a company based in Framingham, medical devices, announced today that it has raised $ 20.5 million in Series C Funding The product will be used to begin commercialization of MyoSure system, easy to use, minimally invasive treatment to remove uterine fibroids and polyps. Proceeds also support the clinical evaluation of the system S useful in an office based environment. HLM Venture Partners and Baird Venture Partners led the round along with Hambrecht and Quist Capital Management LLC Aperture Venture Partners. Existing Investors, New Leaf Venture Partners and Spray Venture Partners also participated in the round. br Fibroids are a common cause of abnormal uterine bleeding, which affects over 10 million women in the United States. The MyoSure system S innovative design quickly and safely removes uterine fibroids and polyps, while Affording physicians the flexibility to conduct procedures in either an operating room or office setting. By developing costeffective and technologically advanced devices that improve patient care, reduce costs and improve efficiency of medical response to interlace a persistent need for increased security, less invasive gynecological procedures. br We are very pleased to join this group of firstlevel investors to launch our initial product, Said Bill Gruber, president of Interlace. There is a great need for less invasive solutions that provide safe, reliable and fast for the removal of fibroids and polyps. MyoSure procedure offers women an excellent alternative to conventional surgical treatments. br Women S of the health sector has long been an underserved market in dire need of better medical solutions as an alternative to traditional surgery and drug therapies Said Michael Liang, Ph.D., Director Baird Venture Partners. Interlace has focused on a particular sector, where treatment options are not ideal, and we believe that interlace has developed and patented a unique system that will be welcomed by gynecologic surgeons. br br
